Michael Ehlers
Neuroscience Chief Scientific Officer
Pfizer
From this contributor
A cautionary tale for autism drug development
Poorly designed animal drug studies for motor disorders have led to spurious conclusions for the clinical trials that follow. This may be even more true for autism research, says Michael Ehlers.
SHANK mutations converge at neuronal junctions in autism
SHANK3, one of the strongest candidate genes for autism, has the potential to be a molecular entry point into understanding the synaptic, developmental and circuit origins of the disorder.
SHANK mutations converge at neuronal junctions in autism
Drug zone
Rodent and stem cell models remain challenging for developing psychiatric drugs, says Michael Ehlers, chief scientific officer of neuroscience at Pfizer.
Explore more from The Transmitter
Double-duty neurons in primary olfactory cortex pick up on more than just scent
The cells recognize not only odors, such as bananas and black licorice—but also images and words associated with those smells, according to single-neuron recordings from 17 people.
Double-duty neurons in primary olfactory cortex pick up on more than just scent
The cells recognize not only odors, such as bananas and black licorice—but also images and words associated with those smells, according to single-neuron recordings from 17 people.
How neuroscience comics add KA-POW! to the field: Q&A with Kanaka Rajan
The artistic approach can help explain complex ideas frame by frame without diluting the science, Rajan says.
How neuroscience comics add KA-POW! to the field: Q&A with Kanaka Rajan
The artistic approach can help explain complex ideas frame by frame without diluting the science, Rajan says.
Former Columbia University psychiatrist committed research misconduct, says federal watchdog
Bret Rutherford, whose research was halted following a suicide in a clinical trial, falsely reported participant eligibility, according to the U.S. Office of Research Integrity.
Former Columbia University psychiatrist committed research misconduct, says federal watchdog
Bret Rutherford, whose research was halted following a suicide in a clinical trial, falsely reported participant eligibility, according to the U.S. Office of Research Integrity.